Fluvastatin inhibits hepatitis C replication in humans. - Wikidata - wikimedia - TriplyDB

Fluvastatin inhibits hepatitis C replication in humans.

Fluvastatin inhibits hepatitis C replication in humans.

http://www.wikidata.org/entity/Q34769764

about

Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms Pleiotropic effects of statins in the diseases of the liver Statins and its hepatic effects: Newer data, implications, and changing recommendations Curing a viral infection by targeting the host: the example of cyclophilin inhibitors Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization Targeting host factors: A novel rationale for the management of hepatitis C virus Class III Phosphatidylinositol 4-Kinase Alpha and Beta Are Novel Host Factor Regulators of Hepatitis C Virus Replication Do statins reduce hepatitis C RNA titers during routine clinical use?Ethanol Enhances Hepatitis C Virus Replication through Lipid Metabolism and Elevated NADH/NAD+Effects of Interferons and Viruses on Metabolism Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis Finding candidate drugs for hepatitis C based on chemical-chemical and chemical-protein interactions Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?Synthesis of New Functionalized Indoles Based on Ethyl Indol-2-carboxylate.Complementary transcriptomic, lipidomic, and targeted functional genetic analyses in cultured Drosophila cells highlight the role of glycerophospholipid metabolism in Flock House virus RNA replication Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.Statin efficacy in the treatment of hepatitis C genotype I.Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro.Associations between serum lipids and hepatitis C antiviral treatment efficacy.Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells Review article: prescribing medications in patients with cirrhosis - a practical guide.Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism.Matrix conditions and KLF2-dependent induction of heme oxygenase-1 modulate inhibition of HCV replication by fluvastatin.Lipid metabolism and HCV infection Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients.Statin Hepatotoxicity: Is it a Real Concern?Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses.Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis.Type I Interferon Counteracts Antiviral Effects of Statins in the Context of Gammaherpesvirus Infection.Raloxifene inhibits hepatitis C virus infection and replication.Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease.Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes.Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling.Chemoprevention for hepatocellular carcinoma: the role of statins.The myth of statin-induced hepatotoxicity.Unique ties between hepatitis C virus replication and intracellular lipids.

P2860

Q24653950-8ED1746D-355C-4837-B2E3-D2D6AB1D24EB Q26741176-F07254FF-4C59-49B8-B501-745211DCB6C0 Q26767065-544CBC25-CBE5-4DEB-80A5-E14366DFC45F Q26828727-1EAA1DD6-D231-4F6D-A51A-509870C11398 Q26864485-477F67A7-38DE-4DF2-A678-AC1197A83FED Q27488999-92BAED20-7B61-4FEE-BC53-1F1E065F1FD5 Q27489697-A64D93E9-ACBF-4BB4-ACF8-EB5983B979EC Q27490248-5635B3D6-4EF5-4265-8CD9-749A6B298B2E Q27490772-EDECD457-B3E2-4007-B12C-2A28F89E8728 Q28353943-862C2B1A-C664-4711-9F09-A0392CA5FEE2 Q28477369-237A3574-3D96-462E-8EA7-C0D1D16E6284 Q28543010-650410DA-E0F4-4BF8-8276-EBF7173A369D Q30369757-071AC593-2F38-496B-8453-2838FE71004A Q31058551-639EC262-9E89-4728-8F99-D58BE532FACC Q33541729-98E2A71D-D716-4F75-AC43-03D34CBEFD29 Q33765060-B4229546-94D2-4FF3-A4C0-35445537DCCA Q33833270-78AB6746-343D-462F-871D-244D64EC0646 Q33848190-E7EF36EF-568C-46F1-AD72-B45FBAD21995 Q34124888-B5BE4874-823C-462E-B99A-D1074655AC6E Q34182524-62A1E6D4-030F-40CC-B4B9-C6825AA31A27 Q34342554-21832AE7-83A0-44C1-B930-216E2F79D391 Q34747195-130E1A7E-DC01-46AE-82F5-E90FCFF2E93E Q35048926-7DA9180B-99FB-4339-93B5-E78ADABAE218 Q35163716-90719A5D-AA3A-43C5-AF41-0A710F7AC73E Q35275932-AAB0C202-7BF9-44AF-90A8-1464AF8A8247 Q35507354-62AF2A06-3AC2-491F-BA1D-982E5B14624C Q35936329-4780FF8A-6F3C-4CF4-AFFE-170BFEFED145 Q36026554-044DE159-2898-4695-8D5C-4ED811FB7A55 Q36425870-2536675A-9F12-4B21-B3CB-B1B189EDB3EB Q36505496-C5EF04CF-FB09-4830-8103-64736F635298 Q36694053-711F952C-68BE-4C2D-A75C-52778E2A40D1 Q36811933-2E7D7090-8400-424F-8B9D-AF6655BBC971 Q37015738-8A1C506A-F282-4D88-8DA9-F4CA890617C3 Q37029796-2B4713F0-8FAA-4E90-ADE1-1A45BFAFF30C Q37179559-163DD808-6AC8-42E0-8580-035CF5955A30 Q37304715-34165486-593E-49FC-B836-422C2295638C Q37400658-BCAD78B8-158A-41EB-B82B-13803759B79D Q37584611-39EFA80C-CFF0-4A15-8667-1BCAF6ABF645 Q37743155-16352634-6D6B-4BC2-BCED-EA7533A7460A Q37865821-FD5CBF14-2615-46EC-8D3A-A7916B7DD143

P2860

Fluvastatin inhibits hepatitis C replication in humans.

http://www.wikidata.org/entity/Q34769764

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Fluvastatin inhibits hepatitis C replication in humans.

@ast

Fluvastatin inhibits hepatitis C replication in humans.

@en

Fluvastatin inhibits hepatitis C replication in humans.

@nl

type

label

Fluvastatin inhibits hepatitis C replication in humans.

@ast

Fluvastatin inhibits hepatitis C replication in humans.

@en

Fluvastatin inhibits hepatitis C replication in humans.

@nl

prefLabel

Fluvastatin inhibits hepatitis C replication in humans.

@ast

Fluvastatin inhibits hepatitis C replication in humans.

@en

Fluvastatin inhibits hepatitis C replication in humans.

@nl

P1433

Q34769764-12D85278-AF71-468B-A5E5-5F85887A36E6

P1476

Q34769764-1CB8B043-D2C5-4F6C-B67F-73C9F207AC39

P2093

Q34769764-09DA90B0-3E35-4BBA-B50D-B22988052523

Q34769764-37611DD3-23EE-4993-9731-6EFE53355E96

Q34769764-3A7B3753-F602-4E95-8A5F-C02BB89D663F

Q34769764-3E9C91A6-427C-4A1B-AC34-814FDE93E525

Q34769764-AA37B18E-981B-46A3-9AA5-A0B351601B90

Q34769764-B6DC8A51-5D09-467F-8C8C-3E870BB9B714

Q34769764-BB19A216-5146-4CB0-B735-31FA6FD6E89E

Q34769764-E532C517-6B23-46A1-8A3D-B628C794C476

P2860

Q34769764-0D16259F-CBAD-4B32-ACCD-CD37DC258408

Q34769764-27D8F70E-630F-44B1-AF9E-67EE297D686A

Q34769764-353CEEE8-5124-4F0A-B0F4-7BB2DC6D8BA0

Q34769764-52B5AD42-BCBD-4C38-B6A0-6AA1819C8370

Q34769764-53642559-596D-4E50-984E-CDB68CCF80DA

Q34769764-54BECBD0-DD04-4785-BEF5-10C872598FD9

Q34769764-6CB6147D-8986-46E5-B15C-88F9541591DB

Q34769764-7EE62526-8E2F-4A9F-8544-3F5278AE0954

Q34769764-929D326C-5E34-4A4A-BDA2-84875D186B9B

Q34769764-92B7DCFB-FB2D-4108-8A88-F6804CBB0896

P304

Q34769764-FE3C1243-B080-4F1E-820F-11D2CDF29B26

P31

Q34769764-AFE3E29A-8814-4E3C-81CB-20C317D2C0A3

P356

Q34769764-66D8B063-414A-456E-A32C-424627213AE8

P407

Q34769764-A13C4F22-ADCD-4D3A-8167-E64D535680EA

P433

Q34769764-0CB2BFFA-0AB4-4B38-B584-6ACF8B9070B7

P478

Q34769764-8889B5B5-6A5A-449E-AE3D-8B49807978D5

P577

Q34769764-6B3075CC-76CB-479B-86C8-ECA93E61BB31

P5875

Q34769764-AD29E8F3-1E6C-4433-8B22-DADABE4E8E99

P698

Q34769764-B7821625-696B-4043-BBDD-28742609A150

P356

J.1572-0241.2008.01876.X

P1433

The American Journal of Gastroenterology

P1476

Fluvastatin inhibits hepatitis C replication in humans.

@en

P2093

Christopher Aston

http://www.w3.org/2001/XMLSchema#string

Diane Hughes

http://www.w3.org/2001/XMLSchema#string

Javid Fazili

http://www.w3.org/2001/XMLSchema#string

Ken Seres

http://www.w3.org/2001/XMLSchema#string

Mohammed Madhoun

http://www.w3.org/2001/XMLSchema#string

Muhammad Hasan

http://www.w3.org/2001/XMLSchema#string

Syed Rizvi

http://www.w3.org/2001/XMLSchema#string

Ted Bader

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication

Hepatitis C Lipo-Viro-Particle from Chronically Infected Patients Interferes with TLR4 Signaling in Dendritic Cell

A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication.

Mechanisms and significance of liver steatosis in hepatitis C virus infection

Different anti-HCV profiles of statins and their potential for combination therapy with interferon.

Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.

Hepatitis C virus particles and lipoprotein metabolism.

Peginterferon and ribavirin for chronic hepatitis C.

Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts.

Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection.

P304

1383-1389

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1572-0241.2008.01876.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5443172

http://www.w3.org/2001/XMLSchema#string

P698

18410471

http://www.w3.org/2001/XMLSchema#string